2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 10 of 645 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05395624 (ClinicalTrials.gov)	February 2, 2023	13/5/2022	A Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging Agent, 18F-OP-801 ...	A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging Agent, 18 ...	Amyotrophic Lateral Sclerosis (ALS)	Drug: 18F-OP-801	Ashvattha Therapeutics, Inc.	NULL	Recruiting	18 Years	80 Years	All	26	Phase 1	United States
2	NCT05695521 (ClinicalTrials.gov)	January 30, 2023	3/1/2023	Regulatory T Cells for Amyotrophic Lateral Sclerosis	Phase 1 Safety Run-in Study and Phase 1b Randomized, Double Blinded, Placebo Controlled Trial	Amyotrophic Lateral Sclerosis	Biological: CK0803;Other: Excipient	Cellenkos, Inc.	NULL	Not yet recruiting	18 Years	95 Years	All	66	Phase 1	United States
3	NCT04505358 (ClinicalTrials.gov)	January 2023	23/7/2020	Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis	A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Biological Activity, Safe ...	Amyotrophic Lateral Sclerosis (ALS)	Drug: PU-AD;Drug: Placebo	Samus Therapeutics, Inc.	NULL	Withdrawn	20 Years	80 Years	All	0	Phase 2	NULL
4	NCT05619783 (ClinicalTrials.gov)	December 29, 2022	27/10/2022	Extension Study Evaluating The Safety And Tolerability of AMX0035	A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 ...	Amyotrophic Lateral Sclerosis	Drug: AMX0035	Amylyx Pharmaceuticals Inc.	NULL	Enrolling by invitation	18 Years	N/A	All	600	Phase 3	Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
5	EUCTR2022-002348-33-ES (EUCTR)	22/12/2022	27/09/2022	A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 ...	A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 ...	ALS(amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: ...	Product Code: AMX0035 INN or Proposed INN: PHENYLBUTYRATE Other descriptive name: PHENYLBUTYRATE INN or ...	Amylyx Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	Portugal;France;United States;Belgium;Poland;Spain;Ireland;Germany;Netherlands;United Kingdom;Italy; ...
6	NCT05633459 (ClinicalTrials.gov)	December 16, 2022	21/11/2022	A Study Evaluating the Safety and Tolerability of QRL-201 in ALS	A Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending Dose Study to Evaluat ...	Amyotrophic Lateral Sclerosis	Drug: QRL-201 - Dose 1;Drug: QRL-201 - Dose 2;Drug: QRL-201 - Dose 3;Drug: QRL-201 - Dose 4;Drug: QR ...	QurAlis Corporation	NULL	Recruiting	18 Years	80 Years	All	64	Phase 1	Canada
7	NCT05683860 (ClinicalTrials.gov)	December 14, 2022	4/1/2023	Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral ...	A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinic ...	ALS;FTD	Drug: WVE-004	Wave Life Sciences Ltd.	NULL	Enrolling by invitation	N/A	N/A	All	42	Phase 1/Phase 2	Netherlands
8	EUCTR2022-002348-33-NL (EUCTR)	06/12/2022	11/10/2022	A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 ...	A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 ...	ALS(amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: ...	Product Code: AMX0035 INN or Proposed INN: PHENYLBUTYRATE Other descriptive name: PHENYLBUTYRATE INN or ...	Amylyx Pharmaceuticals Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	600	Phase 3	Portugal;France;United States;Belgium;Spain;Poland;Ireland;Germany;Netherlands;United Kingdom;Italy; ...
9	NCT05189106 (ClinicalTrials.gov)	December 5, 2022	30/11/2021	Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial	Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis(NADALS) Basket Proof of Conc ...	Amyotrophic Lateral Sclerosis;Alzheimer Disease;Mild Cognitive Impairment	Drug: Baricitinib	Massachusetts General Hospital	NULL	Recruiting	18 Years	90 Years	All	20	Phase 1/Phase 2	United States
10	NCT05003921 (ClinicalTrials.gov)	December 2022	6/8/2021	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injecti ...	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injecti ...	Amyotrophic Lateral Sclerosis	Biological: AlloRx	The Foundation for Orthopaedics and Regenerative Medicine	NULL	Suspended	N/A	N/A	All	20	Phase 1	Antigua and Barbuda

First Previous1 2 3 4 5…65Next Last